STOCK TITAN

Bioxytran launches A-SUQAR and V-LO supplements

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

BIOXYTRAN, INC. (BIXT) announced the launch of A-SUQAR, a post-meal blood sugar supplement, and V-LO, an immune-support supplement, expanding beyond its pharmaceutical pipeline into consumer wellness. Bioxytran describes A-SUQAR as slowing the breakdown and absorption of dietary sugars in the intestine and says it is designed to help maintain healthy blood sugar levels after meals; V-LO is formulated to support healthy immune function.

The company says both products use ingredients Generally Recognized as Safe (GRAS), are made in a certified facility, and were tested by an independent third party. Bioxytran states that the product claims have not been evaluated by the Food and Drug Administration and that the products are not intended to diagnose, treat, cure, or prevent any disease.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
nutraceutical products medical
"launch of two nutraceutical products"
Generally Recognized as Safe (GRAS) regulatory
"ingredients that are Generally Recognized as Safe (GRAS)"
A regulatory designation meaning a substance added to food is considered safe based on a long history of common use or widespread expert agreement, so it does not require the same formal pre-market approval as a new food additive. For investors, GRAS status reduces regulatory risk and speeds time to market—similar to having a fast-pass at a theme park—so products using GRAS ingredients face fewer hurdles, lower costs, and more predictable sales prospects.
complex carbohydrate chemistry technical
"expertise in complex carbohydrate chemistry"
Glycovirology medical
"platform technologies spanning Glycovirology"
hypoxia medical
"platform technologies spanning Glycovirology, hypoxia"
Hypoxia is a condition in which tissues or organs do not get enough oxygen to function properly, similar to being in a room with the air partly taken away. It matters to investors because it drives demand and risk for medical products, clinical trial outcomes, regulatory decisions, and workplace or equipment safety—factors that can affect a company’s revenue, costs, and valuation when treatments, devices, or safety measures are required or tested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are Bioxytran’s new BIXT products?

Bioxytran launched A-SUQAR, formulated to help maintain healthy blood sugar levels after meals, and V-LO, formulated to support healthy immune function. The company says A-SUQAR slows the breakdown and absorption of dietary sugars in the intestine.

Where can I buy Bioxytran’s BIXT supplements?

A-SUQAR and V-LO are available immediately at Bioxytran’s online store: https://bioxytran.myshopify.com.

Have Bioxytran’s BIXT supplement statements been evaluated by the FDA?

Bioxytran states that the product statements have not been evaluated by the Food and Drug Administration and that the products are not intended to diagnose, treat, cure, or prevent any disease.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001445815 0001445815 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

BIOXYTRAN, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   001-35027   26-2797630
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification Number)

 

75 Second Ave, Suite 605, Needham, MA   02494
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code 617-454-1199

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Common Stock, par value $0.001   BIXT   OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events

 

On November 16, 2026, the Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title:

 

Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit

Number

  Description
     
99.1 * Press Release dated November 16, 2026, entitled “Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products”.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed as an exhibit hereto.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOXYTRAN, INC.
     
  By: /s/ David Platt, Ph.D.
    David Platt, Ph.D., its Chief Executive Officer
     
Date November 16, 2026    

 

 

 

 

EXHIBIT 99.1

 

Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products

 

Company applies its carbohydrate-chemistry expertise to consumer wellness with a post-meal blood sugar supplement and an immune support supplement

 

Boston, Mass., November 16, 2026 – Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning Glycovirology, hypoxia, and degenerative diseases, today announced the launch two nutraceutical products: A-SUQAR, a supplement formulated to help maintain healthy blood sugar levels after meals, and V-LO, a supplement formulated to support healthy immune function. These statements have not been evaluated by the Food and Drug Administration, and the products are not intended to diagnose, treat, cure, or prevent any disease.

 

The launch marks Bioxytran’s expansion beyond its pharmaceutical pipeline into the consumer wellness market. A-SUQAR and V-LO are available beginning immediately at https://bioxytran.myshopify.com/

 

“For years, our team has worked on complex therapeutics for critical care and infectious diseases. Today we are bringing that same science directly to people’s doorsteps,” said David Platt, Ph.D., Chief Executive Officer of Bioxytran. “Our entry into nutraceuticals is driven by a simple principle: apply rigorous scientific standards to everyday health. We have held these products to the same diligence we apply to our drug programs, so consumers get a high-quality, science-backed supplement they can trust.”

 

The Products

 

A-SUQAR – Metabolic Support. A-SUQAR is designed to help maintain healthy blood sugar levels after meals. It works by slowing the breakdown and absorption of dietary sugars in the intestine, supporting healthy metabolism and balanced energy throughout the day.

 

V-LO – Immune Support. V-LO is formulated to support the body’s natural immune defenses, helping people stay strong and resilient through the seasons.

 

Built on Safety and Quality

 

Both products draw on Bioxytran’s expertise in complex carbohydrate chemistry and are formulated with ingredients that are Generally Recognized as Safe (GRAS). The products are manufactured in a certified facility and were tested by third independent party.

 

Message to Shareholders and Friends

 

“Our shareholders and friends, are the backbone of Bioxytran,” said Dr. Platt. “We believe the best way to show the value of our work is to experience it firsthand. I invite you to try these products and make them part of your everyday routine. Thank you for your continued faith in Bioxytran. We look forward to sharing more updates on our progress.”

 

About Bioxytran, Inc.

 

Bioxytran, Inc. (OTCQB: BIXT) is a clinical-stage biotechnology company developing platform technologies spanning Glycovirology, hypoxia, and degenerative diseases. The Company is now also applying its scientific expertise to high-quality nutraceutical products. For more information, visit www.bioxytraninc.com.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the launch, availability, market acceptance, and potential benefits of the Company’s nutraceutical products and the Company’s growth. Words such as “believe,” “expect,” “intend,” “plan,” “may,” “will,” and similar expressions identify forward-looking statements. These statements are based on current expectations and involve risks and uncertainties, including risks related to manufacturing and supply, consumer demand, competition, regulatory requirements applicable to dietary supplements, and the Company’s ability to fund its operations. Actual results may differ materially. Additional risks are described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Bioxytran undertakes no obligation to update any forward-looking statement, except as required by law.

 

Contact

 

David Platt, PhD/CEO

Bioxytran, Inc.

Info@bioxytraninc.com

Phone: 617.454.1199

www.bioxytraninc.com

 

 

Filing Exhibits & Attachments

4 documents

Keep reading